GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
		(Unaudited) (Refer Note 2)	(Unaudited)	(Unaudited) (Refer Note 2)	(Audited)	(Audited)
	Income					
1	Revenue from operations	96608	94636	91087	372349	340725
2	Other income	3946	3506	2987	14256	12348
3	Total Income (1+2)	100554	98142	94074	386605	353073
	Expenses				1.44	
	(a) Cost of materials consumed	10835	9193	19229	47086	50499
	(b) Purchases of stock-in-trade	29140	16423	25574	84511	85308
	(c) Changes in inventories of finished goods, stock-in-					
	trade and work-in-progress	(5341)	9528	(9890)	5123	(6964
	(d) Employee benefits expense	15297	12474	17283	57970	62439
	(e) Finance costs	58	9	77	131	180
	(f) Depreciation and amortisation expense	1472	1880	1810	6679	6968
	(g) Other expenses	13603	18000	13360	60730	59378
4	Total expenses	65064	67507	67443	262230	257808
	Profit before exceptional items and tax (3-4)	35490	30635	26631	124375	9526
6	Exceptional items [credit/(charge)] (Refer Note 3)	27.600	-	240	469	(14361
8	Profit before tax (5+6)	35490	30635	26871	124844	80904
0	Tax expense (a) Current tax	8934	7305	6116	32318	23571
	(b) Deferred tax	542	472	1447	620	(1136
9	Profit for the period/year (7-8)	26014	22858	19308	91906	58469

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
		(Unaudited) (Refer Note 2)	(Unaudited)	(Unaudited) (Refer Note 2)	(Audited)	(Audited)
10	Other comprehensive income (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be	(512)	157	(91)	(355)	(557)
	reclassified to profit or loss	128	(39)	22	89	140
11	Total comprehensive income for the period (9+10)	25630	22976	19239	91640	58052
	Paid-up equity share capital (face value per share Rs. 10) Other equity Earnings per share (EPS) (of Rs. 10 each)	16941	16941	16941	16941 177982	16941 161468
	Basic and diluted EPS before Exceptional items (Rs.) Basic and diluted EPS after Exceptional items (Rs.)	15.35 15.35	13.49 13.49	11.29 11.39	54.01 54.24	40.83 34.51
			Not Ann	nualised		

	Statement of Assets and Liabilities	Standalone (Rs. in Lakhs)
	Particulars	As at 31.03.2025	As at 31.03.2024
_		Audited	Audited
1	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	26029	27936
	(b) Right of use Assets	925	1744
	(c) Capital work-in-progress	1432	1393
	(d) Investment Property	76	90
	(e) Intangible assets	1333	2355
	(f) Financial Assets		
	i. Investments	2449	2449
	ii. Loans	400	1100
	iii.Other financial assets	1147	1019
	(g) Current tax assets (net)	19281	20846
	(h) Deferred tax assets (net)	14064	14595
	(i) Other non-current assets	4602	4668
	Total non-current assets	71738	78195
	Current assets		
	(a) Inventories	46317	51430
	(b) Financial assets		
	(i) Current Investments	111825	81322
	(ii) Trade receivables	29255	22206
	(iii) Cash and cash equivalents	53622	6215
	(iv) Bank balances other than (iii) above	86467	99905
	(v) Other financial assets	6564	11150
	(c) Other current assets	4305	4357
	Total current assets	338355	276585
	Total Assets	410093	354780

	Statement of Assets and Liabilities	Standalone (Rs. in Lakhs)		
	Particulars	As at 31.03.2025	As at 31.03.2024	
в ес	DUITY AND LIABILITIES	Audited	Audited	
-	uity			
	Equity Share Capital	16941	1694	
	Other Equity	177982	16146	
	tal equity	194923	17840	
Lia	abilities			
1 No	on-current liabilities			
(a)) Financial Liabilities			
	i. Lease liabilities	249	6	
100	ii. Other financial liabilities	-		
(b)) Provisions	24840	2462	
To	otal non-current liabilities	25089	2527	
2 <u>Cu</u>	rrent liabilities			
(a)) Financial Liabilities			
	i. Lease liabilities	746	122	
	ii.Trade payables			
	Due to Micro Enterprises and Small Enterprises	845	19	
	Due to others	69555	6113	
	iii.Other financial liabilities	17702	1421	
	Other current liabilities	7140	512	
	Provisions	41641	3935	
) Current tax liabilities (net)	52452	2985	
То	otal current liabilities	190081	15109	
To	otal liabilities	215170	176371	
To	otal equity and liabilities	410093	354780	

	Statement of Cash Flows		Standalone (Rs. in LakJs)		
	Particulars		Year ended 31.03.2025	Year ended 31.03.2024	
			Audited	Audited	
١.	CASH FLOWS FROM OPERATING ACTIVITIES				
١.	Profit before exceptional items and tax from :		124375	95265	
	Adjustments for :				
	Loss / (Gain) on disposal of property, plant and equipment (net)		151	(89	
	Interest income	4	(7132)	(6854	
	Gain on liquid investments	1	(6965)	(4878	
	Finance costs	- 1	131	180	
	Depreciation and amortisation expense	1	6679	6968	
	Allowance for doubtful debts and advances		238	59	
	Operating Profit before working capital changes		117477	90651	
	Change in operating assets and liabilities				
	Decrease/(Increase) in inventories		5113	(7659	
	(Increase) in trade receivables	1	(7287)	(3027	
	Decrease in other assets	- 1	4411	604	
	Increase in trade payables	1	8490	18735	
	Increase/(Decrease) in provisions		2153	(3718	
	Increase in other liabilities		5739	1519	
	Cash generated from operations	1	136096	97105	
	Income taxes paid (net of refunds)		(8093)	(25267	
	Cash inflow from operating activities before exceptional items		128003	71838	
	Exceptional items :				
	Payment of redundancy cost		- 1	(16330	
	Income taxes on exceptional items		- 1	2385	
	Net cash generated from operating activities	(A)	128003	57893	

Particulars	Year ended 31.03.2025	Year ended 31.03.2024
	Audited	Audited
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments to acquire property, plant and equipment and other intangible assets	(2302)	(3122)
Proceeds from sale of property, plant and equipment	102	277
Sale / redemption of mutual funds	186063	215610
Margin money deposits (placed) / matured	1	224
Investment/Redemption in bank deposits (having original maturity more than 3	_ ~	
months but less than 12 months)	(329655)	(337930)
Redemption / maturity of bank deposits (having original maturity more than 3		
months but less than 12 months)	343497	350076
Investment in mutual funds	(214348)	(242294)
Loan given to related parties	-	(3300)
Loan repayment from related parties	700	11010
Interest received	11886	9429
Cash (outflow) from investing activities before exceptional items	(4056)	(20)
Exceptional items:		
Proceeds from sale of property	469	1969
Income taxes on Exceptional items	(67)	(452)
Net cash (outflow)/inflow from investing activities (B)	(3654)	1497

CASH FLOWS FROM FINANCING ACTIVITIES Interest paid, other than on lease liabilities		(13)	(22)
Interest paid on lease liabilities		(118)	(157)
Principal payment of lease liabilities		(1873)	(1813)
Dividend paid to company's shareholders		(74938)	(54157)
Net cash outflow from financing activities	(c)	(76942)	(56149)
Net increase in cash and cash equivalents	(A+B+C)	47407	3241
Cash and cash equivalents at the beginning of the year	_ '	6215	2974
Cash and cash equivalents at the end of the year	× .	53622	6215
Net increase in cash and cash equivalents		47407	3241

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective
 meetings held on 13th May 2025. The Statutory auditors have performed audit of the Standalone financial results for the year
 ended 31st March 2025 and limited review of financial results for the quarter ended 31st March 2025 and have issued an
 unmodified opinion.
- The figures for the 3 months ended 31st March 2025 and corresponding 3 months ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the respective financial years.
- 3. Exceptional items pertaining to the period / year :
 - (a) Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties and for the previous year ended 31st March 2024 of Rs. 14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
 - (b) Exceptional items charge for the quarter ended 31st March 2024 of Rs.240 lakhs is on account of profit on sale of surplus residential properties.
- 4. The Board of Directors recommend a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs.32 per equity share).
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board

Bhushan Akshikar Managing Director

DIN: 09112346

13th May, 2025